PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsSulfadiazine
Sulfadiazine
Neotrizine, Sulfadiazine, Sulfonamides Duplex (sulfadiazine) is a small molecule pharmaceutical. Sulfadiazine was first approved as Sulfadiazine on 1982-01-01. It is used to treat aids-related opportunistic infections, bacterial infections, chancroid, enterobacteriaceae infections, and malaria amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
otorhinolaryngologic diseasesD010038
nervous system diseasesD009422
eye diseasesD005128
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Sulfadiazine (discontinued: Sulfadiazine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sulfadiazine
Tradename
Company
Number
Date
Products
SULFADIAZINEAbbVieN-004125 DISCN1982-01-01
1 products
SULFADIAZINELederle LaboratoriesN-004054 DISCN1982-01-01
1 products
SULFADIAZINEEli LillyN-004122 DISCN1982-01-01
1 products, RLD
Hide discontinued
Sulfadiazine sodium
Tradename
Company
Number
Date
Products
SULFADIAZINE SODIUMLederle LaboratoriesN-004054 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
silvadeneNew Drug Application2023-12-09
silver sulfadiazeneNew Drug Application2018-04-19
silver sulfadiazineNew Drug Application2025-02-24
ssdNew Drug Application2024-11-08
ssd creamNew Drug Application2025-03-10
sulfadiazineANDA2024-09-24
thermazeneNew Drug Application2024-08-09
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06B: Chemotherapeutics for topical use
— D06BA: Sulfonamides, topical
— D06BA01: Silver sulfadiazine
— D06BA51: Silver sulfadiazine, combinations
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01E: Sulfonamides and trimethoprim antibacterials for systemic use
— J01EC: Intermediate-acting sulfonamides
— J01EC02: Sulfadiazine
— J01EE: Combinations of sulfonamides and trimethoprim, incl. derivatives
— J01EE02: Sulfadiazine and trimethoprim
— J01EE06: Sulfadiazine and tetroxoprim
HCPCS
No data
Clinical
Clinical Trials
207 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10———1—1
Pulmonary hypertensionD006976EFO_0001361I27.20———1—1
Autonomic nervous system diseasesD001342EFO_0009532G90———1—1
Systemic sclerodermaD012595EFO_0000717M34———1—1
Connective tissue diseasesD003240EFO_1001986M35———1—1
Pulmonary arterial hypertensionD000081029—————1—1
Familial primary pulmonary hypertensionD065627—I27.0———1—1
Diffuse sclerodermaD045743EFO_0000404————1—1
SclerosisD012598—————1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSulfadiazine
INNsulfadiazine sodium
Description
Sulfadiazine is a sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position. It has a role as an antimicrobial agent, an antiinfective agent, a coccidiostat, an antiprotozoal drug, an EC 2.5.1.15 (dihydropteroate synthase) inhibitor, an EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor, a xenobiotic, an environmental contaminant and a drug allergen. It is a member of pyrimidines, a sulfonamide, a substituted aniline and a sulfonamide antibiotic. It is functionally related to a sulfanilamide. It is a conjugate acid of a sulfadiazinate.
Classification
Small molecule
Drug classantimicrobials (sulfonamides derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1
Identifiers
PDB—
CAS-ID68-35-9
RxCUI—
ChEMBL IDCHEMBL439
ChEBI ID9328
PubChem CID5215
DrugBankDB00359
UNII ID84CS1P306F (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Sulfadiazine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 14,850 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,372 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use